HSBC TUR.WAR.OP.END. NOVA/ DE000TT9BHF8 /
17/10/2024 08:02:01 | Chg.+0.020 | Bid09:14:43 | Ask09:14:43 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
14.800EUR | +0.14% | 14.700 Bid Size: 10,000 |
14.840 Ask Size: 10,000 |
Novo Nordisk | 37.9535 USD | 31/12/2078 | Call |
Newsfile Corp
28/08
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...
GlobeNewswire
28/08
Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising A...
GlobeNewswire
28/08
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
GlobeNewswire
27/08
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Chil...
GlobeNewswire
26/08
Dewpoint Therapeutics Awarded Target ALS Grant for the Second Time for Development of c-mods for Amy...
GlobeNewswire
21/08
ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing
GlobeNewswire
14/08
19th Annual Cardiometabolic Health Congress: Honoring the Life and Legacy of CMHC Co-Chair Dr. Georg...
GlobeNewswire
06/08
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...
GlobeNewswire
01/08
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Dire...
GlobeNewswire
11/07
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansio...
GlobeNewswire
11/07
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pi...
GlobeNewswire
11/07
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pi...